DUBLIN--(BUSINESS WIRE)--The "Advancements in Gene Therapy, Synthetic Biology, Diagnostic Assays, Imaging Tracers, and Biopharma" report has been added to ResearchAndMarkets.com's offering.
The Life Science, Health & Wellness TechVision Opportunity Engine (TOE) provides recent advances across bioCDMO, synthetic biology, diagnostics and biopharma landscapes.
The TOE provides analytical insights across Cyrus Bench, On/Off Synbio Switches, On-Point Solutions, Extremozymes, IQVIA Core, Homologus recombination, biopharmaceutical manufacturing, diagnostics, imaging, and cell therapy platforms.
Key Topics Covered:
- Exploring the Potential of Novel Platforms in Life Sciences
- Cloud-based Molecular Modeling and Protein Design
- On/Off Switches for Genetically Modified Organisms
- On-Point Solutions for a Smart Lab
- Extremozymes for Therapeutics Development
- Leveraging Human Data Science and Advanced Analytics for Clinical Genomics
- Leveraging Homologous Recombination for Gene Editing
- Advancing the Manufacture of Viral Vectors
- Accelerating the Development of Biopharmaceutical Products
- Promising Preclinical Data for off-the-shelf Cell Therapy
- Tau PET Imaging Tracer, APN-1607 Licensed for Use in Tauopathy Clinical Studies
- Prognostic and Diagnostic Cancer Screening Assays
- Encouraging Interim Clinical Results of GoCAR-T Cell Therapy Candidate
- Industry Relations
- Regional Practice Leaders and Innovation Experts
For more information about this report visit https://www.researchandmarkets.com/research/l5sxxb/advancements_in?w=4
